Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Integrating Regulatory Drug Label Information to Facilitate Evaluation of Adverse Events in Pharmacovigilance

Author(s): Tom Z. Hui*

Volume 15, Issue 2, 2020

Page: [124 - 130] Pages: 7

DOI: 10.2174/1574886315666200224101011

Price: $65

Abstract

Background: Efficiency and accuracy for signal detection and evaluation activities are integral components of routine Pharmacovigilance (PV) practices. However, an Individual Case Safety Report (ICSR) may consist of a variety of confounders such as Concomitant Medications (CM), Past Medical History (PMH), and concurrent medical conditions that influence a safety officer’s evaluation of a potential Adverse Event (AE). Limited pharmacovigilance systems are currently available as a tool designed to enhance the efficiency and accuracy of signal detection and management.

Objective: To introduce a systemic approach to make critical safety information readily available for users in order to discern possible interferences from CM and make informed decisions on the signal evaluation process – saving time while improving quality.

Methods: Oracle Empirica Signal software was utilized to extract cases with CM that are Known Implicating Medications (KIM) for each AE according to public regulatory information from drug labels – FDA Structured Product Labeling (SPL) or EMA Summary of Product Characteristics (SPC). SAS Enterprise Guide was used to further process the data generated from Oracle Empirica Signal software.

Results: For any target drug being evaluated for safety purposes, a KIM reference table can be generated, which summarizes all potential causality contributions from CMs.

Conclusion: In addition to providing standalone KIM table as reference, adoption of this concept and automation may also be fully integrated into commercial signal detection and management software packages for easy use and accessibility and may even lead to reduced False Positive rate in signal detection within the PV space.

Keywords: Patient safety, drug safety, pharmacovigilance, adverse event, adverse reaction, signal detection, clinical trial, postmarketing surveillance.

« Previous Next »
Graphical Abstract

[1]
WHO The importance of pharmacovigilance (Safety monitoring of medicinal products) World Health Organization . 2002. Available from https://apps.who.int/iris/bitstream/handle/10665/42493/a75646.pdf
[2]
European Medicines Agency Guideline on good pharmacovigilance practices (GVP) Module IX-Signal management (Rev 1). 2017. Available from https://www.ema.europa.eu/en/ documents/ scientific
[3]
Caster O, Sanberg L, Bergvall T, Watson S, Norến GN. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use. Pharmacoepidemiol Drug Saf 2017; 26: 1006-10.
[http://dx.doi.org/10.1002/pds.4247] [PMID: 28653790 ]
[4]
Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: How The European Union pharmacovigilance system works. Drug Saf 2017; 40(10): 855-69.
[http://dx.doi.org/10.1007/s40264-017-0572-8] [PMID: 28735357]
[5]
Subeesh V, Maheswari E, Sarawathy GR, Swaroop AM, Minnikanti SS. A comparative study of data mining algorithms used for signal detection in FDA AERS database. J Young Pharm 2018; 10(4): 444-9.
[http://dx.doi.org/10.5530/jyp.2018.10.97]
[6]
Osbourne V, Shakir SAW. The 9th Biennial Conference on signal detection and interpretation in pharmacovigilance. Drug Saf 2017; 41: 139-41.
[http://dx.doi.org/10.1007/s40264-017-0587-1] [PMID: 28795368]
[7]
Seabroke S, Wise L, Waller P. Development of a novel regulatory pharmacovigilance prioritisation system: An evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency. Drug Saf 2013; 36(10): 1025-32.
[http://dx.doi.org/10.1007/s40264-013-0081-3] [PMID: 23821159]
[8]
Patadia VK, Coloma P, Schuemie MJ, et al. Using real-world healthcare data for pharmacovigilance signal detection-the experience of the EU-ADR project. Expert Rev Clin Pharmacol 2015; 8(1): 95-102.
[http://dx.doi.org/10.1586/17512433.2015.992878]
[9]
Bie SD, Ferrajolo C, Straus SM, et al. Pediatric drug safety surveillance in FDA-AERS: A description of adverse events from grip project. PLoS One 2015; 10(6)e0130399
[http://dx.doi.org/10.1371/journal.pone.0130399] [PMID: 26090678]
[10]
Harpaz R, DuMouchel W, LePendu P, Bauer MA, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 2013; 93(6): 539-46.
[http://dx.doi.org/10.1038/clpt.2013.24]]
[11]
UMC VigiBase. Uppsala Monitoring Centre: WHO Collaborating Centre for International Drug Monitoring. Available from: https://www.who-umc.org/vigibase/vigibase/
[12]
Wisniewski AFZ, Bate A, Bousquet C, et al. Good signal detection practices: Evidence from IMI PROTECT. Drug Saf 2016; 39(6): 469-90.
[http://dx.doi.org/10.1007/s40264-016-0405-1] [PMID: 26951233]
[13]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154]
[14]
Suzuki A, Yuen NA, Ilic K, et al. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. Regul Toxicol Pharmacol 2015; 72(3): 481-90.
[http://dx.doi.org/10.1016/j.yrtph.2015.05.004] [PMID: 25988394]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy